Neurostimulation Devices Comprehensive Study by Type (Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), Spinal Cord Stimulation (SCS), Gastric Electrical Stimulation (GES), Vagus Nerve Stimulation (VNS), Others), Application (Dystonia, Epilepsy, Pain Management, Tremors, Parkinson's disease, Depression, Gastroparesis, Urinary And Fecal Incontinence, Others) Players and Region - Global Market Outlook to 2027

Neurostimulation Devices Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 11.7%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Neurostimulation Devices Market Scope
Neurostimulation device is a surgically placed device which is used for the treatment of the neurologic disorder that helps in the delivery of electric stimulation to intended part of patient’s brain, spinal cord and peripheral nervous system. Device used for neuromodulation is also known as neurostimulators or neurostimulation devices.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledNeuronetics Inc., Medtronic Inc., LivaNova PLC (United Kingdom), Neurosigma Inc., Boston Scientific Corporation (United States), St. Jude Medical Inc. (United States), MED-EL GmbH (Germany), Nevro Corporation (United States) and Neuropace Inc. (United States)
CAGR11.7%


"According to AMA, the Global Neurostimulation Devices market is expected to see growth rate of 11.7% and may see market size of USD1027.0 Million by 2027."

Market players are focusing on providing Neurostimulation Devices with higher quality along with complying all regulatory standards for the patients. They are also focusing on the introduction of numerous advanced & attractive features to further offer qualified devices. The market is fragmented owing to the presence of several international and domestic providers. The high focus on the offering cost effective product offerings. Besides, the numerous industry profitability has led the entry of new players, in turn, increasing the level of rivalry in the already competitive market. Research Analyst at AMA estimates that United States and United Kingdom Players will contribute to the maximum growth of Global Neurostimulation Devices market throughout the predicted period.

Neuronetics Inc., Medtronic Inc., LivaNova PLC (United Kingdom), Neurosigma Inc., Boston Scientific Corporation (United States), St. Jude Medical Inc. (United States), MED-EL GmbH (Germany), Nevro Corporation (United States) and Neuropace Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are BioControl Medical (Israel), Synapse Biomedical Inc. and Cyberonics Inc..

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Neurostimulation Devices market by Type , by Application (Dystonia, Epilepsy, Pain Management, Tremors, Parkinson's disease, Depression, Gastroparesis, Urinary And Fecal Incontinence and Others) and Region with country level break-up.

On the basis of geography, the market of Neurostimulation Devices has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2021.

Market Leaders and their expansionary development strategies
In 2020, Cirtec Medical Corporation had acquired intellectual property and certain assets from Nuvectra Corporation. Cirtec is a strategic outsourcing partner for complex medical devices including active implantable and minimally invasive devices. With these acquistion, Cirtec has leveraged this technology to support customers’ development of neuromodulation products, providing an FDA approved platform with a complete design history file to leverage for a variety of therapeutic applications.
In April 2022, Abbott has revamped the digital health app used alongside its neurostimulation devices for chronic pain. This digital health app is helping doctor to track how patients are managing the treatment is better. It is specially designed to track and report on patient-perceived pain relief and general well-being associated with spinal cord stimulation (SCS).
According to estimates from World Health Organization, depression is the leading cause of ill health globally, more than 300 million people of all ages suffer from depression. Depression is the leading cause of disability worldwide and is a major contributor to the overall global burden of disease. More women are affected by depression than men. Additionally, as per the National Center for Health Statistics of the Centers for Disease Control and Prevention (CDC), 84,767 people had died due to Alzheimer’s disease. Each year nearly, 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally.

Neurostimulation Devices Market Dynamics:
AttributesDetails
Trends Influencing Market
  • Technology Advancement In Manufacturing Process of Neurostimulation Devices
Key Restraints
  • Unfriendly Reimbursement Schemes from Government in Different Countries
Challenges
  • Side Effects on User Body Caused By Neurostimulation Devices
  • Lack of Skilled Professionals
  • High Making Cost of Neurostimulation Devices and Its Management Is Major Challenge for the Market
Market Opportunities
  • Increase In Research and Development Investments for The Development Neurostimulation Devices


Key Target Audience
Neurostimulation Devices Manufacturers, Neurostimulation Devices Supplier, Raw Material Supplier, Contract Research Organizations (Cros), Government & Independent Research Laboratories, Research And Development (R&D) Companies, Market Research And Consulting Service Providers, Government And Independent Regulatory Authorities and Academic Institutes And Universities

Report Objectives / Segmentation Covered

By Type
  • Deep Brain Stimulation (DBS)
  • Sacral Nerve Stimulation (SNS)
  • Spinal Cord Stimulation (SCS)
  • Gastric Electrical Stimulation (GES)
  • Vagus Nerve Stimulation (VNS)
  • Others
By Application
  • Dystonia
  • Epilepsy
  • Pain Management
  • Tremors
  • Parkinson's disease
  • Depression
  • Gastroparesis
  • Urinary And Fecal Incontinence
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population
      • 3.2.2. Increasing Awareness about Mental Diseases and Their Treatment
    • 3.3. Market Challenges
      • 3.3.1. Side Effects on User Body Caused By Neurostimulation Devices
      • 3.3.2. Lack of Skilled Professionals
      • 3.3.3. High Making Cost of Neurostimulation Devices and Its Management Is Major Challenge for the Market
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement In Manufacturing Process of Neurostimulation Devices
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurostimulation Devices, by Type, Application and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Neurostimulation Devices (Value)
      • 5.2.1. Global Neurostimulation Devices by: Type (Value)
        • 5.2.1.1. Deep Brain Stimulation (DBS)
        • 5.2.1.2. Sacral Nerve Stimulation (SNS)
        • 5.2.1.3. Spinal Cord Stimulation (SCS)
        • 5.2.1.4. Gastric Electrical Stimulation (GES)
        • 5.2.1.5. Vagus Nerve Stimulation (VNS)
        • 5.2.1.6. Others
      • 5.2.2. Global Neurostimulation Devices by: Application (Value)
        • 5.2.2.1. Dystonia
        • 5.2.2.2. Epilepsy
        • 5.2.2.3. Pain Management
        • 5.2.2.4. Tremors
        • 5.2.2.5. Parkinson's disease
        • 5.2.2.6. Depression
        • 5.2.2.7. Gastroparesis
        • 5.2.2.8. Urinary And Fecal Incontinence
        • 5.2.2.9. Others
      • 5.2.3. Global Neurostimulation Devices Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Neurostimulation Devices (Volume)
      • 5.3.1. Global Neurostimulation Devices by: Type (Volume)
        • 5.3.1.1. Deep Brain Stimulation (DBS)
        • 5.3.1.2. Sacral Nerve Stimulation (SNS)
        • 5.3.1.3. Spinal Cord Stimulation (SCS)
        • 5.3.1.4. Gastric Electrical Stimulation (GES)
        • 5.3.1.5. Vagus Nerve Stimulation (VNS)
        • 5.3.1.6. Others
      • 5.3.2. Global Neurostimulation Devices by: Application (Volume)
        • 5.3.2.1. Dystonia
        • 5.3.2.2. Epilepsy
        • 5.3.2.3. Pain Management
        • 5.3.2.4. Tremors
        • 5.3.2.5. Parkinson's disease
        • 5.3.2.6. Depression
        • 5.3.2.7. Gastroparesis
        • 5.3.2.8. Urinary And Fecal Incontinence
        • 5.3.2.9. Others
      • 5.3.3. Global Neurostimulation Devices Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Neurostimulation Devices (Price)
      • 5.4.1. Global Neurostimulation Devices by: Type (Price)
  • 6. Neurostimulation Devices: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Neuronetics Inc.
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medtronic Inc.
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. LivaNova PLC (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Neurosigma Inc.
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boston Scientific Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. St. Jude Medical Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MED-EL GmbH (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Nevro Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Neuropace Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Neurostimulation Devices Sale, by Type, Application and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Neurostimulation Devices (Value)
      • 7.2.1. Global Neurostimulation Devices by: Type (Value)
        • 7.2.1.1. Deep Brain Stimulation (DBS)
        • 7.2.1.2. Sacral Nerve Stimulation (SNS)
        • 7.2.1.3. Spinal Cord Stimulation (SCS)
        • 7.2.1.4. Gastric Electrical Stimulation (GES)
        • 7.2.1.5. Vagus Nerve Stimulation (VNS)
        • 7.2.1.6. Others
      • 7.2.2. Global Neurostimulation Devices by: Application (Value)
        • 7.2.2.1. Dystonia
        • 7.2.2.2. Epilepsy
        • 7.2.2.3. Pain Management
        • 7.2.2.4. Tremors
        • 7.2.2.5. Parkinson's disease
        • 7.2.2.6. Depression
        • 7.2.2.7. Gastroparesis
        • 7.2.2.8. Urinary And Fecal Incontinence
        • 7.2.2.9. Others
      • 7.2.3. Global Neurostimulation Devices Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Neurostimulation Devices (Volume)
      • 7.3.1. Global Neurostimulation Devices by: Type (Volume)
        • 7.3.1.1. Deep Brain Stimulation (DBS)
        • 7.3.1.2. Sacral Nerve Stimulation (SNS)
        • 7.3.1.3. Spinal Cord Stimulation (SCS)
        • 7.3.1.4. Gastric Electrical Stimulation (GES)
        • 7.3.1.5. Vagus Nerve Stimulation (VNS)
        • 7.3.1.6. Others
      • 7.3.2. Global Neurostimulation Devices by: Application (Volume)
        • 7.3.2.1. Dystonia
        • 7.3.2.2. Epilepsy
        • 7.3.2.3. Pain Management
        • 7.3.2.4. Tremors
        • 7.3.2.5. Parkinson's disease
        • 7.3.2.6. Depression
        • 7.3.2.7. Gastroparesis
        • 7.3.2.8. Urinary And Fecal Incontinence
        • 7.3.2.9. Others
      • 7.3.3. Global Neurostimulation Devices Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Neurostimulation Devices (Price)
      • 7.4.1. Global Neurostimulation Devices by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurostimulation Devices: by Type(USD Million)
  • Table 2. Neurostimulation Devices Deep Brain Stimulation (DBS) , by Region USD Million (2016-2021)
  • Table 3. Neurostimulation Devices Sacral Nerve Stimulation (SNS) , by Region USD Million (2016-2021)
  • Table 4. Neurostimulation Devices Spinal Cord Stimulation (SCS) , by Region USD Million (2016-2021)
  • Table 5. Neurostimulation Devices Gastric Electrical Stimulation (GES) , by Region USD Million (2016-2021)
  • Table 6. Neurostimulation Devices Vagus Nerve Stimulation (VNS) , by Region USD Million (2016-2021)
  • Table 7. Neurostimulation Devices Others , by Region USD Million (2016-2021)
  • Table 8. Neurostimulation Devices: by Application(USD Million)
  • Table 9. Neurostimulation Devices Dystonia , by Region USD Million (2016-2021)
  • Table 10. Neurostimulation Devices Epilepsy , by Region USD Million (2016-2021)
  • Table 11. Neurostimulation Devices Pain Management , by Region USD Million (2016-2021)
  • Table 12. Neurostimulation Devices Tremors , by Region USD Million (2016-2021)
  • Table 13. Neurostimulation Devices Parkinson's disease , by Region USD Million (2016-2021)
  • Table 14. Neurostimulation Devices Depression , by Region USD Million (2016-2021)
  • Table 15. Neurostimulation Devices Gastroparesis , by Region USD Million (2016-2021)
  • Table 16. Neurostimulation Devices Urinary And Fecal Incontinence , by Region USD Million (2016-2021)
  • Table 17. Neurostimulation Devices Others , by Region USD Million (2016-2021)
  • Table 18. South America Neurostimulation Devices, by Country USD Million (2016-2021)
  • Table 19. South America Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 20. South America Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 21. Brazil Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 22. Brazil Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 23. Argentina Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 24. Argentina Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 25. Rest of South America Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 26. Rest of South America Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 27. Asia Pacific Neurostimulation Devices, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 29. Asia Pacific Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 30. China Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 31. China Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 32. Japan Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 33. Japan Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 34. India Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 35. India Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 36. South Korea Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 37. South Korea Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 38. Taiwan Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 39. Taiwan Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 40. Australia Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 41. Australia Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 42. Rest of Asia-Pacific Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 43. Rest of Asia-Pacific Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 44. Europe Neurostimulation Devices, by Country USD Million (2016-2021)
  • Table 45. Europe Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 46. Europe Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 47. Germany Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 48. Germany Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 49. France Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 50. France Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 51. Italy Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 52. Italy Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 53. United Kingdom Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 54. United Kingdom Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 55. Netherlands Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 56. Netherlands Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 57. Rest of Europe Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 58. Rest of Europe Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 59. MEA Neurostimulation Devices, by Country USD Million (2016-2021)
  • Table 60. MEA Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 61. MEA Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 62. Middle East Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 63. Middle East Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 64. Africa Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 65. Africa Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 66. North America Neurostimulation Devices, by Country USD Million (2016-2021)
  • Table 67. North America Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 68. North America Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 69. United States Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 70. United States Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 71. Canada Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 72. Canada Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 73. Mexico Neurostimulation Devices, by Type USD Million (2016-2021)
  • Table 74. Mexico Neurostimulation Devices, by Application USD Million (2016-2021)
  • Table 75. Neurostimulation Devices Sales: by Type(K Units)
  • Table 76. Neurostimulation Devices Sales Deep Brain Stimulation (DBS) , by Region K Units (2016-2021)
  • Table 77. Neurostimulation Devices Sales Sacral Nerve Stimulation (SNS) , by Region K Units (2016-2021)
  • Table 78. Neurostimulation Devices Sales Spinal Cord Stimulation (SCS) , by Region K Units (2016-2021)
  • Table 79. Neurostimulation Devices Sales Gastric Electrical Stimulation (GES) , by Region K Units (2016-2021)
  • Table 80. Neurostimulation Devices Sales Vagus Nerve Stimulation (VNS) , by Region K Units (2016-2021)
  • Table 81. Neurostimulation Devices Sales Others , by Region K Units (2016-2021)
  • Table 82. Neurostimulation Devices Sales: by Application(K Units)
  • Table 83. Neurostimulation Devices Sales Dystonia , by Region K Units (2016-2021)
  • Table 84. Neurostimulation Devices Sales Epilepsy , by Region K Units (2016-2021)
  • Table 85. Neurostimulation Devices Sales Pain Management , by Region K Units (2016-2021)
  • Table 86. Neurostimulation Devices Sales Tremors , by Region K Units (2016-2021)
  • Table 87. Neurostimulation Devices Sales Parkinson's disease , by Region K Units (2016-2021)
  • Table 88. Neurostimulation Devices Sales Depression , by Region K Units (2016-2021)
  • Table 89. Neurostimulation Devices Sales Gastroparesis , by Region K Units (2016-2021)
  • Table 90. Neurostimulation Devices Sales Urinary And Fecal Incontinence , by Region K Units (2016-2021)
  • Table 91. Neurostimulation Devices Sales Others , by Region K Units (2016-2021)
  • Table 92. South America Neurostimulation Devices Sales, by Country K Units (2016-2021)
  • Table 93. South America Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 94. South America Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 95. Brazil Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 96. Brazil Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 97. Argentina Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 98. Argentina Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 99. Rest of South America Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 100. Rest of South America Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 101. Asia Pacific Neurostimulation Devices Sales, by Country K Units (2016-2021)
  • Table 102. Asia Pacific Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 103. Asia Pacific Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 104. China Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 105. China Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 106. Japan Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 107. Japan Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 108. India Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 109. India Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 110. South Korea Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 111. South Korea Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 112. Taiwan Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 113. Taiwan Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 114. Australia Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 115. Australia Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 116. Rest of Asia-Pacific Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 117. Rest of Asia-Pacific Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 118. Europe Neurostimulation Devices Sales, by Country K Units (2016-2021)
  • Table 119. Europe Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 120. Europe Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 121. Germany Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 122. Germany Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 123. France Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 124. France Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 125. Italy Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 126. Italy Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 127. United Kingdom Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 128. United Kingdom Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 129. Netherlands Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 130. Netherlands Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 131. Rest of Europe Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 132. Rest of Europe Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 133. MEA Neurostimulation Devices Sales, by Country K Units (2016-2021)
  • Table 134. MEA Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 135. MEA Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 136. Middle East Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 137. Middle East Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 138. Africa Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 139. Africa Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 140. North America Neurostimulation Devices Sales, by Country K Units (2016-2021)
  • Table 141. North America Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 142. North America Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 143. United States Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 144. United States Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 145. Canada Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 146. Canada Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 147. Mexico Neurostimulation Devices Sales, by Type K Units (2016-2021)
  • Table 148. Mexico Neurostimulation Devices Sales, by Application K Units (2016-2021)
  • Table 149. Neurostimulation Devices: by Type(USD/Units)
  • Table 150. Company Basic Information, Sales Area and Its Competitors
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Neurostimulation Devices: by Type(USD Million)
  • Table 160. Neurostimulation Devices Deep Brain Stimulation (DBS) , by Region USD Million (2022-2027)
  • Table 161. Neurostimulation Devices Sacral Nerve Stimulation (SNS) , by Region USD Million (2022-2027)
  • Table 162. Neurostimulation Devices Spinal Cord Stimulation (SCS) , by Region USD Million (2022-2027)
  • Table 163. Neurostimulation Devices Gastric Electrical Stimulation (GES) , by Region USD Million (2022-2027)
  • Table 164. Neurostimulation Devices Vagus Nerve Stimulation (VNS) , by Region USD Million (2022-2027)
  • Table 165. Neurostimulation Devices Others , by Region USD Million (2022-2027)
  • Table 166. Neurostimulation Devices: by Application(USD Million)
  • Table 167. Neurostimulation Devices Dystonia , by Region USD Million (2022-2027)
  • Table 168. Neurostimulation Devices Epilepsy , by Region USD Million (2022-2027)
  • Table 169. Neurostimulation Devices Pain Management , by Region USD Million (2022-2027)
  • Table 170. Neurostimulation Devices Tremors , by Region USD Million (2022-2027)
  • Table 171. Neurostimulation Devices Parkinson's disease , by Region USD Million (2022-2027)
  • Table 172. Neurostimulation Devices Depression , by Region USD Million (2022-2027)
  • Table 173. Neurostimulation Devices Gastroparesis , by Region USD Million (2022-2027)
  • Table 174. Neurostimulation Devices Urinary And Fecal Incontinence , by Region USD Million (2022-2027)
  • Table 175. Neurostimulation Devices Others , by Region USD Million (2022-2027)
  • Table 176. South America Neurostimulation Devices, by Country USD Million (2022-2027)
  • Table 177. South America Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 178. South America Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 179. Brazil Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 180. Brazil Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 181. Argentina Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 182. Argentina Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 183. Rest of South America Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 184. Rest of South America Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 185. Asia Pacific Neurostimulation Devices, by Country USD Million (2022-2027)
  • Table 186. Asia Pacific Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 187. Asia Pacific Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 188. China Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 189. China Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 190. Japan Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 191. Japan Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 192. India Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 193. India Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 194. South Korea Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 195. South Korea Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 196. Taiwan Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 197. Taiwan Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 198. Australia Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 199. Australia Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 202. Europe Neurostimulation Devices, by Country USD Million (2022-2027)
  • Table 203. Europe Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 204. Europe Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 205. Germany Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 206. Germany Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 207. France Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 208. France Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 209. Italy Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 210. Italy Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 211. United Kingdom Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 212. United Kingdom Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 213. Netherlands Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 214. Netherlands Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 215. Rest of Europe Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 216. Rest of Europe Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 217. MEA Neurostimulation Devices, by Country USD Million (2022-2027)
  • Table 218. MEA Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 219. MEA Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 220. Middle East Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 221. Middle East Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 222. Africa Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 223. Africa Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 224. North America Neurostimulation Devices, by Country USD Million (2022-2027)
  • Table 225. North America Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 226. North America Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 227. United States Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 228. United States Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 229. Canada Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 230. Canada Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 231. Mexico Neurostimulation Devices, by Type USD Million (2022-2027)
  • Table 232. Mexico Neurostimulation Devices, by Application USD Million (2022-2027)
  • Table 233. Neurostimulation Devices Sales: by Type(K Units)
  • Table 234. Neurostimulation Devices Sales Deep Brain Stimulation (DBS) , by Region K Units (2022-2027)
  • Table 235. Neurostimulation Devices Sales Sacral Nerve Stimulation (SNS) , by Region K Units (2022-2027)
  • Table 236. Neurostimulation Devices Sales Spinal Cord Stimulation (SCS) , by Region K Units (2022-2027)
  • Table 237. Neurostimulation Devices Sales Gastric Electrical Stimulation (GES) , by Region K Units (2022-2027)
  • Table 238. Neurostimulation Devices Sales Vagus Nerve Stimulation (VNS) , by Region K Units (2022-2027)
  • Table 239. Neurostimulation Devices Sales Others , by Region K Units (2022-2027)
  • Table 240. Neurostimulation Devices Sales: by Application(K Units)
  • Table 241. Neurostimulation Devices Sales Dystonia , by Region K Units (2022-2027)
  • Table 242. Neurostimulation Devices Sales Epilepsy , by Region K Units (2022-2027)
  • Table 243. Neurostimulation Devices Sales Pain Management , by Region K Units (2022-2027)
  • Table 244. Neurostimulation Devices Sales Tremors , by Region K Units (2022-2027)
  • Table 245. Neurostimulation Devices Sales Parkinson's disease , by Region K Units (2022-2027)
  • Table 246. Neurostimulation Devices Sales Depression , by Region K Units (2022-2027)
  • Table 247. Neurostimulation Devices Sales Gastroparesis , by Region K Units (2022-2027)
  • Table 248. Neurostimulation Devices Sales Urinary And Fecal Incontinence , by Region K Units (2022-2027)
  • Table 249. Neurostimulation Devices Sales Others , by Region K Units (2022-2027)
  • Table 250. South America Neurostimulation Devices Sales, by Country K Units (2022-2027)
  • Table 251. South America Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 252. South America Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 253. Brazil Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 254. Brazil Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 255. Argentina Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 256. Argentina Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 257. Rest of South America Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 258. Rest of South America Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 259. Asia Pacific Neurostimulation Devices Sales, by Country K Units (2022-2027)
  • Table 260. Asia Pacific Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 261. Asia Pacific Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 262. China Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 263. China Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 264. Japan Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 265. Japan Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 266. India Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 267. India Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 268. South Korea Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 269. South Korea Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 270. Taiwan Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 271. Taiwan Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 272. Australia Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 273. Australia Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 274. Rest of Asia-Pacific Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 275. Rest of Asia-Pacific Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 276. Europe Neurostimulation Devices Sales, by Country K Units (2022-2027)
  • Table 277. Europe Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 278. Europe Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 279. Germany Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 280. Germany Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 281. France Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 282. France Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 283. Italy Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 284. Italy Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 285. United Kingdom Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 286. United Kingdom Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 287. Netherlands Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 288. Netherlands Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 289. Rest of Europe Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 290. Rest of Europe Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 291. MEA Neurostimulation Devices Sales, by Country K Units (2022-2027)
  • Table 292. MEA Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 293. MEA Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 294. Middle East Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 295. Middle East Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 296. Africa Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 297. Africa Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 298. North America Neurostimulation Devices Sales, by Country K Units (2022-2027)
  • Table 299. North America Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 300. North America Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 301. United States Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 302. United States Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 303. Canada Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 304. Canada Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 305. Mexico Neurostimulation Devices Sales, by Type K Units (2022-2027)
  • Table 306. Mexico Neurostimulation Devices Sales, by Application K Units (2022-2027)
  • Table 307. Neurostimulation Devices: by Type(USD/Units)
  • Table 308. Research Programs/Design for This Report
  • Table 309. Key Data Information from Secondary Sources
  • Table 310. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurostimulation Devices: by Type USD Million (2016-2021)
  • Figure 5. Global Neurostimulation Devices: by Application USD Million (2016-2021)
  • Figure 6. South America Neurostimulation Devices Share (%), by Country
  • Figure 7. Asia Pacific Neurostimulation Devices Share (%), by Country
  • Figure 8. Europe Neurostimulation Devices Share (%), by Country
  • Figure 9. MEA Neurostimulation Devices Share (%), by Country
  • Figure 10. North America Neurostimulation Devices Share (%), by Country
  • Figure 11. Global Neurostimulation Devices: by Type K Units (2016-2021)
  • Figure 12. Global Neurostimulation Devices: by Application K Units (2016-2021)
  • Figure 13. South America Neurostimulation Devices Share (%), by Country
  • Figure 14. Asia Pacific Neurostimulation Devices Share (%), by Country
  • Figure 15. Europe Neurostimulation Devices Share (%), by Country
  • Figure 16. MEA Neurostimulation Devices Share (%), by Country
  • Figure 17. North America Neurostimulation Devices Share (%), by Country
  • Figure 18. Global Neurostimulation Devices: by Type USD/Units (2016-2021)
  • Figure 19. Global Neurostimulation Devices share by Players 2021 (%)
  • Figure 20. Global Neurostimulation Devices share by Players (Top 3) 2021(%)
  • Figure 21. Global Neurostimulation Devices share by Players (Top 5) 2021(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Neuronetics Inc. Revenue, Net Income and Gross profit
  • Figure 24. Neuronetics Inc. Revenue: by Geography 2021
  • Figure 25. Medtronic Inc. Revenue, Net Income and Gross profit
  • Figure 26. Medtronic Inc. Revenue: by Geography 2021
  • Figure 27. LivaNova PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. LivaNova PLC (United Kingdom) Revenue: by Geography 2021
  • Figure 29. Neurosigma Inc. Revenue, Net Income and Gross profit
  • Figure 30. Neurosigma Inc. Revenue: by Geography 2021
  • Figure 31. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Boston Scientific Corporation (United States) Revenue: by Geography 2021
  • Figure 33. St. Jude Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. St. Jude Medical Inc. (United States) Revenue: by Geography 2021
  • Figure 35. MED-EL GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 36. MED-EL GmbH (Germany) Revenue: by Geography 2021
  • Figure 37. Nevro Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Nevro Corporation (United States) Revenue: by Geography 2021
  • Figure 39. Neuropace Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Neuropace Inc. (United States) Revenue: by Geography 2021
  • Figure 41. Global Neurostimulation Devices: by Type USD Million (2022-2027)
  • Figure 42. Global Neurostimulation Devices: by Application USD Million (2022-2027)
  • Figure 43. South America Neurostimulation Devices Share (%), by Country
  • Figure 44. Asia Pacific Neurostimulation Devices Share (%), by Country
  • Figure 45. Europe Neurostimulation Devices Share (%), by Country
  • Figure 46. MEA Neurostimulation Devices Share (%), by Country
  • Figure 47. North America Neurostimulation Devices Share (%), by Country
  • Figure 48. Global Neurostimulation Devices: by Type K Units (2022-2027)
  • Figure 49. Global Neurostimulation Devices: by Application K Units (2022-2027)
  • Figure 50. South America Neurostimulation Devices Share (%), by Country
  • Figure 51. Asia Pacific Neurostimulation Devices Share (%), by Country
  • Figure 52. Europe Neurostimulation Devices Share (%), by Country
  • Figure 53. MEA Neurostimulation Devices Share (%), by Country
  • Figure 54. North America Neurostimulation Devices Share (%), by Country
  • Figure 55. Global Neurostimulation Devices: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Neuronetics Inc.
  • Medtronic Inc.
  • LivaNova PLC (United Kingdom)
  • Neurosigma Inc.
  • Boston Scientific Corporation (United States)
  • St. Jude Medical Inc. (United States)
  • MED-EL GmbH (Germany)
  • Nevro Corporation (United States)
  • Neuropace Inc. (United States)
Additional players considered in the study are as follows:
BioControl Medical (Israel) , Synapse Biomedical Inc. , Cyberonics Inc.
Select User Access Type

Key Highlights of Report


Jul 2022 178 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Neurostimulation Devices study can be customized to meet your requirements. The market size breakdown by type [Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), Spinal Cord Stimulation (SCS), Gastric Electrical Stimulation (GES), Vagus Nerve Stimulation (VNS) and Others], by end use application [Dystonia, Epilepsy, Pain Management, Tremors, Parkinson's disease, Depression, Gastroparesis, Urinary And Fecal Incontinence and Others].
The Neurostimulation Devices Market is gaining popularity and expected to see strong valuation by 2027.
  • Growing Geriatric Population
  • Increasing Awareness about Mental Diseases and Their Treatment
As per AMA Research, the Global Neurostimulation Devices market is seen at a value of USD427.0 Million.

Know More About Global Neurostimulation Devices research Report?